A Feasibility Study of Patients with Major Depression and Substance Use Disorders : Vortioxetine as Maintenance Treatment (2024)

Basurte-Villamor, I., Vega, P., Martínez-Raga, J., Grau-López, L., Aguilar, L., Torrens, M., & Szerman, N. (2022). A Feasibility Study of Patients with Major Depression and Substance Use Disorders : Vortioxetine as Maintenance Treatment. Neuropsychiatric Disease and Treatment, 18, 0965-976. https://doi.org/10.2147/NDT.S358782

Basurte-Villamor, Ignacio ; Vega, Pablo ; Martínez-Raga, José et al. / A Feasibility Study of Patients with Major Depression and Substance Use Disorders : Vortioxetine as Maintenance Treatment. In: Neuropsychiatric Disease and Treatment. 2022 ; Vol. 18. pp. 0965-976.

@article{ac4716fb151444469f173cfd69c78b29,

title = "A Feasibility Study of Patients with Major Depression and Substance Use Disorders :: Vortioxetine as Maintenance Treatment",

abstract = "Limited studies have evaluated the effectiveness of vortioxetine in real-world settings, and none of them has involved patients with dual depression (major depressive disorder [MDD] and substance use disorder [SUD]). The objective of the study was to describe the effectiveness of vortioxetine in clinical practice and determine its effect on affective symptoms, cognitive function, quality of life, and substance use in patients with MDD and SUD. Post-authorization, retrospective, multicenter, descriptive, and observational study in 80 patients with MDD and SUD receiving a maintenance treatment with vortioxetine for six months between January 2017 and April 2021. Compared with baseline, scores significantly decreased after 3 and 6 months of treatment in the Montgomery-{\AA}sberg Depression Rating Scale total (from 28.9 to 17.7 and 12.0), and global functional impairment of the Sheehan Disability Inventory (from 26.3 to 19.1 and 16.7). The number of correct answers in the symbol digit modalities test significantly improved during vortioxetine treatment (from 40.4 to 43.8 and 48.4). Regarding the clinical global impression scale, the score for disease severity significantly decreased from 3.8 to 3.0 and 2.4. Compared with baseline, there was a significant reduction in consumption of practically all substances, especially of alcohol, cannabis, and cocaine. Vortioxetine was effective in clinical practice for alleviating depressive symptoms and functional impairment, and in improving cognitive and executive functions and disease severity in patients with MDD and SUD. Moreover, the treatment with vortioxetine favored a reduction in substance use and the severity of the SUDs.",

keywords = "Dual disorder, Major depressive disorder, Major dual depressive disorder, Real-world evidence, Substance use disorder, Vortioxetine",

author = "Ignacio Basurte-Villamor and Pablo Vega and Jos{\'e} Mart{\'i}nez-Raga and Lara Grau-L{\'o}pez and Lourdes Aguilar and Marta Torrens and Nestor Szerman",

year = "2022",

doi = "10.2147/NDT.S358782",

language = "English",

volume = "18",

pages = "0965--976",

}

Basurte-Villamor, I, Vega, P, Martínez-Raga, J, Grau-López, L, Aguilar, L, Torrens, M & Szerman, N 2022, 'A Feasibility Study of Patients with Major Depression and Substance Use Disorders : Vortioxetine as Maintenance Treatment', Neuropsychiatric Disease and Treatment, vol. 18, pp. 0965-976. https://doi.org/10.2147/NDT.S358782

A Feasibility Study of Patients with Major Depression and Substance Use Disorders : Vortioxetine as Maintenance Treatment. / Basurte-Villamor, Ignacio; Vega, Pablo; Martínez-Raga, José et al.
In: Neuropsychiatric Disease and Treatment, Vol. 18, 2022, p. 0965-976.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - A Feasibility Study of Patients with Major Depression and Substance Use Disorders :

T2 - Vortioxetine as Maintenance Treatment

AU - Basurte-Villamor, Ignacio

AU - Vega, Pablo

AU - Martínez-Raga, José

AU - Grau-López, Lara

AU - Aguilar, Lourdes

AU - Torrens, Marta

AU - Szerman, Nestor

PY - 2022

Y1 - 2022

N2 - Limited studies have evaluated the effectiveness of vortioxetine in real-world settings, and none of them has involved patients with dual depression (major depressive disorder [MDD] and substance use disorder [SUD]). The objective of the study was to describe the effectiveness of vortioxetine in clinical practice and determine its effect on affective symptoms, cognitive function, quality of life, and substance use in patients with MDD and SUD. Post-authorization, retrospective, multicenter, descriptive, and observational study in 80 patients with MDD and SUD receiving a maintenance treatment with vortioxetine for six months between January 2017 and April 2021. Compared with baseline, scores significantly decreased after 3 and 6 months of treatment in the Montgomery-Åsberg Depression Rating Scale total (from 28.9 to 17.7 and 12.0), and global functional impairment of the Sheehan Disability Inventory (from 26.3 to 19.1 and 16.7). The number of correct answers in the symbol digit modalities test significantly improved during vortioxetine treatment (from 40.4 to 43.8 and 48.4). Regarding the clinical global impression scale, the score for disease severity significantly decreased from 3.8 to 3.0 and 2.4. Compared with baseline, there was a significant reduction in consumption of practically all substances, especially of alcohol, cannabis, and cocaine. Vortioxetine was effective in clinical practice for alleviating depressive symptoms and functional impairment, and in improving cognitive and executive functions and disease severity in patients with MDD and SUD. Moreover, the treatment with vortioxetine favored a reduction in substance use and the severity of the SUDs.

AB - Limited studies have evaluated the effectiveness of vortioxetine in real-world settings, and none of them has involved patients with dual depression (major depressive disorder [MDD] and substance use disorder [SUD]). The objective of the study was to describe the effectiveness of vortioxetine in clinical practice and determine its effect on affective symptoms, cognitive function, quality of life, and substance use in patients with MDD and SUD. Post-authorization, retrospective, multicenter, descriptive, and observational study in 80 patients with MDD and SUD receiving a maintenance treatment with vortioxetine for six months between January 2017 and April 2021. Compared with baseline, scores significantly decreased after 3 and 6 months of treatment in the Montgomery-Åsberg Depression Rating Scale total (from 28.9 to 17.7 and 12.0), and global functional impairment of the Sheehan Disability Inventory (from 26.3 to 19.1 and 16.7). The number of correct answers in the symbol digit modalities test significantly improved during vortioxetine treatment (from 40.4 to 43.8 and 48.4). Regarding the clinical global impression scale, the score for disease severity significantly decreased from 3.8 to 3.0 and 2.4. Compared with baseline, there was a significant reduction in consumption of practically all substances, especially of alcohol, cannabis, and cocaine. Vortioxetine was effective in clinical practice for alleviating depressive symptoms and functional impairment, and in improving cognitive and executive functions and disease severity in patients with MDD and SUD. Moreover, the treatment with vortioxetine favored a reduction in substance use and the severity of the SUDs.

KW - Dual disorder

KW - Major depressive disorder

KW - Major dual depressive disorder

KW - Real-world evidence

KW - Substance use disorder

KW - Vortioxetine

U2 - 10.2147/NDT.S358782

DO - 10.2147/NDT.S358782

M3 - Article

C2 - 35547266

SN - 1178-2021

VL - 18

SP - 965

EP - 976

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

ER -

Basurte-Villamor I, Vega P, Martínez-Raga J, Grau-López L, Aguilar L, Torrens M et al. A Feasibility Study of Patients with Major Depression and Substance Use Disorders : Vortioxetine as Maintenance Treatment. Neuropsychiatric Disease and Treatment. 2022;18:0965-976. doi: 10.2147/NDT.S358782